EI
NVCT icon

EAM Investors’s Nuvectis Pharma NVCT Stock Holding History

EAM Investors’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867K Buy
+47,168
New +$528K 0.08% 236

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

EAM Investors's NVCT Position: Q2 2026 in Review

EAM Investors opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 47,168 shares worth $867K. The stake represents 0.08% of the portfolio and ranks #236 among its holdings.

83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • EAM Investors held 47,168 shares of Nuvectis Pharma worth $867K as of Q2 2026.
  • Nuvectis Pharma was a new EAM Investors position in Q2 2026.
  • Nuvectis Pharma made up 0.08% of EAM Investors's portfolio in Q2 2026, its #236 holding.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.